Raltegravir, sold under the brand name Isentress, is an integrase inhibitor used in combination with other antiretroviral medications to treat HIV/AIDS. It is also used in post-exposure prophylaxis (PEP) to prevent HIV infection after potential exposure. It is taken orally.
![Ethyl [(2-{4-[(4-fluorobenzyl) carbamoyl]-5-hydroxy-1-methyl-6-oxo-1,6-dihydropyrimidin-2-yl} propan-2-yl) amino] (oxo)acetate](https://veeprho.com/wp-content/uploads/2023/01/Ethyl-2-4-4-fluorobenzyl-carbamoyl-5-hydroxy-1-methyl-6-oxo-1-6-dihydropyrimidin-2-yl-propan-2-yl-amino-oxo-acetate.png "Ethyl [(2-{4-[(4-fluorobenzyl) carbamoyl]-5-hydroxy-1-methyl-6-oxo-1,6-dihydropyrimidin-2-yl} propan-2-yl) amino] (oxo)acetate")
Parent: Raltegravir
Parent: Raltegravir
![N-(4-fluorobenzyl)-2-(2-{[hydrazinyl(oxo)acetyl] amino} propan-2-yl)-5-hydroxy-1-methyl-6-oxo-1,6-dihydropyrimidine-4-carboxamide](https://veeprho.com/wp-content/uploads/2023/01/N-4-fluorobenzyl-2-2-hydrazinyl-oxo-acetyl-20amino-propan-2-yl-5-hydroxy-1-methyl-6-oxo-1-6-dihydropyrimidine-4-carboxamide66.png "N-(4-fluorobenzyl)-2-(2-{[hydrazinyl(oxo)acetyl] amino} propan-2-yl)-5-hydroxy-1-methyl-6-oxo-1,6-dihydropyrimidine-4-carboxamide")
Parent: Raltegravir
Parent: Raltegravir
![N-(4-fluorobenzyl)-5-methoxy-2-(2-{[(5-methyl-1,3,4-oxadiazol-2-yl) carbonyl] amino} propan-2-yl)-6-oxo-1,6-dihydropyrimidine-4-carboxamide](https://veeprho.com/wp-content/uploads/2023/01/N-4-fluorobenzyl-5-methoxy-2-2-5-methyl-1-3-4-oxadiazol-2-yl-carbonyl-amino-propan-2-yl-6-oxo-1-6-dihydropyrimidine-4-carboxamide.png "N-(4-fluorobenzyl)-5-methoxy-2-(2-{[(5-methyl-1,3,4-oxadiazol-2-yl) carbonyl] amino} propan-2-yl)-6-oxo-1,6-dihydropyrimidine-4-carboxamide")
Parent: Raltegravir
Parent: Raltegravir
![N1,N2-bis[1-[4-[[[(4-Fluorophenyl)methyl]amino]carbonyl]-1,6-dihydro-5-hydroxy-1-methyl-6-oxo-2-pyrimidinyl]-1-methylethyl]ethanediamide](https://veeprho.com/wp-content/uploads/2023/01/N1-N2-bis-1-4-4-Fluorophenyl-methyl-amino-carbonyl-1-6-dihydro-5-hydroxy-1-methyl-6-oxo-2-pyrimidinyl-1-methylethyl-ethanediamide.png "N1,N2-bis[1-[4-[[[(4-Fluorophenyl)methyl]amino]carbonyl]-1,6-dihydro-5-hydroxy-1-methyl-6-oxo-2-pyrimidinyl]-1-methylethyl]ethanediamide")
Parent: Raltegravir
Parent: Raltegravir
Parent: Raltegravir
Parent: Raltegravir
Parent: Raltegravir
Impurities in Raltegravir can arise from synthesis, degradation, or storage conditions. These impurities must be monitored and controlled to ensure drug safety and efficacy.
Analytical Techniques for Impurity Detection
Yes, common side effects include headache, nausea, diarrhea, dizziness, and fatigue. Rare but serious side effects may include severe allergic reactions, muscle pain, and liver problems.
No, Raltegravir can be taken with or without food. However, taking it with food may help reduce stomach discomfort.
Dolutegravir has a higher barrier to resistance and requires once-daily dosing, while Raltegravir is typically taken twice daily. Dolutegravir is often preferred for treatment-naïve patients due to its longer-lasting effect and lower resistance development.
